Skip to main
XOMA

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty is strategically positioned in the biotechnology space, with a diverse portfolio of early-mid stage clinical assets and a strong track record of acquisitions. Its partnerships with top companies like Moderna and Krystal Biotech demonstrate the potential of its royalty aggregator business model. The recent acquisition of Generation Bio for $35 million in excess cash further strengthens XOMA's financial position. As one of the biotech industry's leading royalty aggregators, XOMA has a promising future ahead with potential monetization of its partnered assets, such as its promising option for ITP patients and potential breakthrough therapy designation for Volixibat. While the recent Phase 3 miss for partner company Rezolute's ersodetug in CHI may have affected its near-term revenue projections, its strong cash balance and continued creativity in transactions make XOMA a strong investment option in the biotech sector.

Bears say

XOMA Royalty is a biotechnology royalty aggregator with a negative outlook as their revenue growth is mainly driven by potential future economics associated with pre-commercial therapeutic candidates and their revenue streams are unpredictable due to the timing of milestone payments. Additionally, despite a strong balance sheet and continued profitability, XOMA's future potential is uncertain due to its recent acquisition by Ligand and a lack of new partnerships. The doubling down on mezagitamab is a positive development, but the undisclosed royalty increase may not significantly impact XOMA's overall revenue. Overall, there are too many uncertainties surrounding XOMA's future, making it a risky investment option.

XOMA (XOMA) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Buy based on their latest research and market trends.

According to 3 analysts, XOMA (XOMA) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.